These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 24136301

  • 1. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
    Rajpal RK, Fong R, Comstock TL.
    Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK, Roel L, Siou-Mermet R, Erb T.
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [Abstract] [Full Text] [Related]

  • 3. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.
    Fong R, Silverstein BE, Peace JH, Williams JI, Vittitow JL.
    J Cataract Refract Surg; 2018 Oct; 44(10):1220-1229. PubMed ID: 30193927
    [Abstract] [Full Text] [Related]

  • 4. Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies.
    Fong R, Cavet ME, DeCory HH, Vittitow JL.
    Clin Ophthalmol; 2019 Oct; 13():1427-1438. PubMed ID: 31447544
    [Abstract] [Full Text] [Related]

  • 5. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [Abstract] [Full Text] [Related]

  • 6. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial.
    Fong R, Leitritz M, Siou-Mermet R, Erb T.
    Clin Ophthalmol; 2012 Sep; 6():1113-24. PubMed ID: 22888209
    [Abstract] [Full Text] [Related]

  • 7. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
    Lane SS, Holland EJ.
    J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery.
    Comstock TL, Paterno MR, Singh A, Erb T, Davis E.
    Clin Ophthalmol; 2011 Feb; 5():177-86. PubMed ID: 21383946
    [Abstract] [Full Text] [Related]

  • 9. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R, Horwitz B, Howes J, Novack GD, Hart K.
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, Hart K.
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
    Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR, Bromfenac Ophthalmic Solution (Bromday) Once Daily Study Group.
    Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992
    [Abstract] [Full Text] [Related]

  • 12. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
    Comstock TL, Paterno MR, Bateman KM, Decory HH, Gearinger M.
    Paediatr Drugs; 2012 Apr 01; 14(2):119-30. PubMed ID: 22292487
    [Abstract] [Full Text] [Related]

  • 13. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, Wang L, Gu Y, Elion-Mboussa A, Roy L, Zhu B.
    Clin Ther; 2012 Jun 01; 34(6):1259-1272.e1. PubMed ID: 22627057
    [Abstract] [Full Text] [Related]

  • 14. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
    Kang C, Keam SJ, Shirley M, Syed YY.
    Clin Drug Investig; 2020 Apr 01; 40(4):387-394. PubMed ID: 32172521
    [Abstract] [Full Text] [Related]

  • 15. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M, Howes J, George M.
    J Ocul Pharmacol Ther; 1998 Dec 01; 14(6):533-42. PubMed ID: 9867336
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial.
    Colin J, Paquette B.
    Clin Ther; 2006 Apr 01; 28(4):527-36. PubMed ID: 16750464
    [Abstract] [Full Text] [Related]

  • 17. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, Solomon KD, McDonald MB, Perry HD, Lane SS, Pflugfelder SC, Samudre SS.
    Eye Contact Lens; 2014 Sep 01; 40(5):289-96. PubMed ID: 25083776
    [Abstract] [Full Text] [Related]

  • 18. Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.
    Vittitow JL, Williams JI.
    J Cataract Refract Surg; 2020 Aug 01; 46(8):1092-1101. PubMed ID: 32352250
    [Abstract] [Full Text] [Related]

  • 19. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR, Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group.
    Ophthalmology; 2007 Sep 01; 114(9):1653-62. PubMed ID: 17445902
    [Abstract] [Full Text] [Related]

  • 20. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P, Howes J.
    CLAO J; 1997 Jan 01; 23(1):31-6. PubMed ID: 9001768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.